MedImpact launches a performance-driven PMPM pricing model, enhancing cost predictability and accountability for health plans amid rising pharmacy expenses.
Formulary Watch
Latest News
All News
Advertisement
Today’s announcement builds on a previous announcement of more than 40% off the Eliquis list price, a direct-to-consumer program that began earlier this month.
FDA rejects Rexulti's approval for PTSD treatment, citing insufficient evidence of effectiveness in combination with sertraline. Otsuka and Lundbeck announced they are planning next steps.
The FDA letter requested that a technical information update be included in the Chemistry Manufacturing and Controls (CMC) module of the sNDA.
Judi Health redefines health benefit management with a $400 million funding boost, enhancing transparency and efficiency for employers and health plans.
The complete response letter was issued by the FDA during a routine inspection of a third-party fill-finish facility, not because of an issue with apitegromab.
Brian K. Lee, Ph.D., of Drexel University Dornsife School of Public Health, says that despite the fact that some studies suggest there is link between acetaminophen use during pregnancy and neurodevelopmental disorders, there is a lack of evidence to support that conclusion.
Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster administration and broader access to immunotherapy.
Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s disease.
Optum Rx has increased brand drug reimbursement minimums for 2,300 independent pharmacies that are not its network.
Advertisement
This spray formulation of bumetanide demonstrated a 33% faster absorption rate than oral bumetanide, according to clinical trial data.
Providers also have concerns about being able to stock certain medications, which would have a negative impact on their patients, according the Avalere Health survey.
Ocaliva, approved for primary biliary cholangitis, faced FDA warnings and restrictions after postmarket data showed higher risks of liver transplant and death among treated patients.
Two separate analyses in Health Affairs find the One Big Beautiful Bill creates a loophole that exempts or delays orphan drugs — many of them blockbuster drugs that generate billions of dollars in sales — from price negotiations.
ICER’s comparative effectiveness and value review of Wegovy, Zepbound and oral semaglutide finds they are highly effective treatments with significant health benefits, but affordability and long-term management are still unresolved.
Leqembi IQLIK, a subcutaneous version of Leqembi, will launch on Oct. 6, 2025, with a list price of $375 per autoinjector.
Liraglutide, a generic of Saxenda, is approved to treat adults and adolescents who are obese or overweight.
In separate announcements, Form Health and 9amHealth said they would provide patients seeking support for obesity care with nutrition and lifestyle support, as well as prescriptions for medications.
Orforglipron will be submitted to global regulatory authorities for the treatment of obesity or for weight loss by the end of 2025, with diabetes submissions to follow in 2026.
A new Business Group on Health survey finds that nearly a quarter of all employer healthcare spending (24%) went to pharmacy expenses in 2024, and employers forecast an 11% to 12% increase in pharmacy costs heading into 2026.
Dawnzera (donidalorsen) will be available in a few days with a list price of $57,462 per dose
The biosimilar will be available to any licensed specialty pharmacy in the United States at a 95% discount from Stelara, starting January 1, 2026.
The FDA has granted priority review of the sNDA and assigned a goal date of Dec. 20, 2025, for Imcivree to treat patients with acquired hypothalamic obesity, which is caused by an abnormality of the hypothalamus.
A new study finds Medicare beneficiaries are facing higher deductibles and cost-sharing requirements following changes implemented by health plans as a result of the Inflation Reduction Act.
Tonmya is the first new fibromyalgia treatment approved by the FDA in more than 15 years, providing symptom relief for at least 30% of patients when compared to placebo, according to clinical trial results.
Wegovy is the first GLP-1 drug approved to treat adults with metabolic dysfunction-associated steatohepatitis (MASH). An ongoing study aims to confirm the benefits.
Advertisement
Advertisement